News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Dapagliflozin in Respiratory failure in patients with COVID-19: An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19

Study Status:

Closed for enrollment

Contact Information:

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To determine whether dapagliflozin 10 mg is superior to placebo, in reducing disease progression, complications, and all-cause mortality in patients hospitalized with COVID-19

Information: 

Principal Investigator
Marcel Twahirwa, MD
Co-PI
Luis Cantu Jr.
Sponsor
St. Luke's Hospital of Kansas City
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram